Opthea Ltd

ASX:OPT ISIN:AU000000OPT2

Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies for cancer and eye diseases. The Company focuses on developing activities that covers targets, including vascular endothelial growth factors (VEGF-C, VEGF-D and VEGF receptor-3). It develops therapies for the treatment of diseases associated with blood and lymphatic vessel growth, such as angiogenesis, lymphangiogenesis and vascular leakage.

 
 
           

Lihat di Bahasa Lain

Berita

Laporan Pasar Australia 6 April 2011: Motopia Limited (ASX:MOT) Mendukung Layanan Online Business Wire Menjangkau Australia Dan Selandia Baru

🕔4/6/2011 12:00:56 PM 32515

Laporan Pasar Australia 6 April memuat: Anak Perusahaan Motopia Limited (ASX:MOT), yaitu cBox Pty Ltd telah ditunjuk sebagai mitra distribusi Australasia dari Business Wire; MACA Limited (ASX:MLD) memberikan layanan pemilihan dan pemecahan biji besi bagi WPG Resources Limited (ASX:WPG); Rey Resources Limited (ASX:REY) mengumumkan kenaikan Sumberdaya Terukur Batubara Termis pada Proyek Duchess Paradise; Circadian Technologies Limited (ASX:CIR) mengatakan bahwa VGX-100 secara signifikan menghambat pertumbuhan dan penyebaran berbagai jenis tumor pada manusia.

Baca Full Story
###

171,189 TAMPILAN PROFIL PERUSAHAAN

  • Halaman ini dilihat: (7 Hari Terakhir: 21) (30 Hari Terakhir: 67) (Sejak Ditampilkan: 12721) 

Data Perusahaan

    Fax
  • (03) 9824 0083 
  • Sektor Utama
  • Kesehatan & Pharm 
  • Industri Utama
  • Biotechnology 
  • Homepage
  • www.opthea.com.au

Lebih banyak Berita lagi

  • 2024/06/12: Update - Proposed issue of securities - OPT*
  • 2024/06/12: Proposed issue of securities - OPT*
  • 2024/06/12: Opthea - Prospectus 2024*
  • 2024/06/12: Opthea Equity Raise Investor Presentation*
  • 2024/06/12: Opthea Annouces Equity Raise*
  • 2024/06/12: Trading Halt - Accelerated Offer*
  • 2024/06/07: Trading Halt*
  • 2024/06/03: Opthea to Present at Clinical Trials at the Summit Meeting*
  • 2024/05/28: Opthea Completes Enrollment in Phase 3 Clinical Program*
  • 2024/05/01: Opthea Announces Presentations at Retina World Congress*
*refer to company website